Research paper
EPISTOP: secondary prevention of epilepsy in tuberous sclerosis complex
EPISTOP secondary-prevention framework. EEG-guided pre-symptomatic vigabatrin started on the basis of pre-seizure EEG abnormalities substantially reduced clinical seizures, drug-resistant epilepsy, and infantile spasms in TSC infants. Establishes the conceptual model of EEG-guided pre-symptomatic intervention in a known mTORopathy.
Specchio N, Jozwiak S, et al.
Markdown path
content/research/papers/2025-specchio-epistop-secondary-prevention-ebiomedicine.mdFindings
EPISTOP secondary-prevention framework. EEG-guided pre-symptomatic vigabatrin started on the basis of pre-seizure EEG abnormalities substantially reduced clinical seizures, drug-resistant epilepsy, and infantile spasms in TSC infants. Establishes the conceptual model of EEG-guided pre-symptomatic intervention in a known mTORopathy.
Why it may matter for Levi
Levi is past the pre-symptomatic window - his epilepsy is established - so direct application is not possible. However, EPISTOP is a critical precedent for mTOR-pathway-targeted therapy in Levi's differential: if a mosaic PI3K-AKT-mTOR variant is confirmed, rapalogs have a proven disease-modifying track record in a related mTORopathy. Useful framing when discussing rapalog therapy with Stanford/UCSF - mechanism-based extension of an established secondary-prevention paradigm.
Specchio et al. (2025) — EPISTOP secondary prevention framework
Source
- EBioMedicine, 2025.
Why in corpus
EPISTOP is the reference trial for pre-symptomatic anti-epileptogenic treatment in tuberous sclerosis complex (TSC). Cited in the 2026 Manus AI review as the template for how mTORopathy-targeted secondary prevention could be extended to other mosaic PI3K-AKT-mTOR disorders — directly relevant to Levi's top differential theory.
Key findings
- Vigabatrin started on the basis of EEG biomarkers (pre-seizure EEG abnormalities) in infants with TSC substantially reduced the incidence of clinical seizures, drug-resistant epilepsy, and infantile spasms.
- Establishes the conceptual model of EEG-guided pre-symptomatic intervention in a known mTORopathy.
- Reinforces that the window for anti-epileptogenic intervention may be early and biomarker-defined rather than seizure-defined.
Levi-relevant takeaways
- Levi is past the pre-symptomatic window — his epilepsy is established — so direct application of EPISTOP is not possible.
- However, EPISTOP is a critical precedent argument for mTOR-pathway-targeted therapy in Levi's differential: if a mosaic PI3K-AKT-mTOR variant is confirmed, rapalogs (everolimus/sirolimus) have a proven disease-modifying track record in a related mTORopathy.
- Useful framing when discussing rapalog therapy with Stanford/UCSF — not an experimental one-off, but a mechanism-based extension of an established secondary-prevention paradigm.
- Also underscores the value of aggressive early biomarker-driven care even in etiologically unclear cases: the EPISTOP lesson is that waiting for clinical deterioration before intervening may be the wrong default.